Advanced Healthcare Materials Submission Guide: How to Submit to AHM (Wiley)

The current Advanced Healthcare Materials author guidelines list Research Articles, Reviews, Perspectives, and Correspondence. Research Articles are unsolicited reports of original research, and Reviews may be submitted without an invitation from the editorial office. The older Guide for Authors PDF lists Communications, Full Papers, Review Articles, Progress Reports, Research News, Essays, and Correspondence instead.

Research Articles are the main unsolicited format. A typical Research Article is around 3,000 to 8,000 words in its entirety, including 3 to 8 display items (figures, schemes, or tables), though submitted manuscripts can be any length as long as the scientific content justifies it, with an abstract of 200 words at most and 3 to 7 keywords.

The older Guide for Authors PDF caps a Full Paper at eight journal pages, approximately 7,500 words and eight display items, which is the stricter figure, so plan the display-item budget with it in mind: biological validation, characterization, and mechanism figures compete for the same space in biomaterials work. If your story needs far more, the work is either a Review-length contribution or it is being framed too broadly.

Communications appear only in the older Guide for Authors PDF, which gives them four journal pages, about 3,000 words and three display items. The current guidelines list no Communication type, so a short report is submitted as a Research Article.

Reviews and Perspectives are peer-reviewed. A typical Review is 10,000 to 20,000 words with 5 to 15 display items; Perspectives can be of any length but are expected to be to the point. Reviews may be submitted without an invitation, but unsolicited submissions judged too specialized for the readership are referred to one or more sister journals or returned without external peer review.

For files, Wiley provides Word and LaTeX templates and asks authors to use them, although a new submission does not need to be reformatted. A new submission needs an editable manuscript file, an ORCID ID, co-author details, and the applicable statements: data availability, funding, conflict of interest, ethics approval, patient consent, permission to reproduce material, and clinical trial registration. The manuscript also carries Table of Contents text of 50 to 60 words and a ToC graphic, and supporting information is optional. The ToC graphic is not decoration here: for a healthcare-materials journal, it is a chance to make the biology visible at a glance instead of leading with a synthesis schematic.

Before the format and declarations are locked, an Advanced Healthcare Materials Full Paper readiness check can confirm whether your biological validation genuinely fits the eight-page Full Paper format or whether the contribution needs reframing.

Advanced Healthcare Materials' review is handled by professional in-house editors on Wiley's submission system and the Advanced portfolio's transfer network. SciRev, where authors report their own experience, shows averages from only 4 author reports (read October 2026): 1.0 months for the first review round, 2.3 review reports and 2.3 review rounds. Treat the SciRev figures as planning ranges, not commitments, since the sample is small; Wiley's own medians are in the last stage below.

• Submission. New submissions go through Wiley Authors using Free Format submission: an editable manuscript file, an ORCID ID, co-author details, and the applicable ethics and integrity statements.

• Editor assessment. All manuscripts are subject to assessment by the editors and/or peer review. The first evaluation of a manuscript rarely results in acceptance, and editors reject manuscripts at this stage if they are insufficiently original, have serious scientific flaws, need extensive improvement in the language, or do not fall within the aims and scope. Manuscripts reporting results with undisclosed material compositions may be returned without external review.

• Peer review. Manuscripts of potential interest to the readership are sent for formal review, handled by professional in-house editors. They are typically sent to at least two reviewers, and the peer-review process is single-anonymous.

• Decision and revision. The editor decides whether to accept, reject, or request revisions. A revised manuscript needs a point-by-point author response letter, with changes highlighted in the "Main document - tracked changes" file and an unmarked clean version uploaded as the primary file.

• Timing and transfer. Wiley's journal metrics for 2025 list a median of 14 days from submission to first decision, 92 days from submission to acceptance, and 12 days from acceptance to publication, with a 22% acceptance rate. If a manuscript is not accepted, the journal may recommend a transfer to another suitable Wiley journal; any Wiley journal with overlapping scope could be a transfer target. Published papers carry a 10.1002/adhm DOI.

In our pre-submission review work with Advanced Healthcare Materials manuscripts, four patterns generate the most consistent early returns. None of them are about the materials chemistry being wrong. They are about whether the biological validation carries the healthcare claim, which is exactly what AHM editors screen for before peer review begins.

In our review of healthcare-materials manuscripts, each of these is a named rejection pattern you can check your own draft against, and each reflects an editorial triage pattern specific to how AHM editors read submissions against the journal's biological-validation bar. The Advanced-portfolio transfer network raises the stakes, because a materials-led manuscript does not just get rejected, it can be offered a transfer to another Wiley journal.

Editors consistently screen for these before sending a manuscript out for review.

Advanced Healthcare Materials author guidelines and the Wiley Guide for Authors define the mechanics below; the patterns describe how manuscripts coming through pre-submission review for this journal most often fall short of them. Most of the attrition we see happens at the editorial-board screen, before reviewers ever weigh in, and these four patterns are why.

A materials-science paper wearing a healthcare label. This is the single most common stall we see at Advanced Healthcare Materials. The synthesis and characterization are strong, the abstract claims biomedical relevance, but the only biology is a sentence that the material is biocompatible. The figures are materials figures: spectra, microscopy, mechanical curves.

An AHM editor reads it and asks the load-bearing question: does the biological validation prove this material improves human health, or is the biology decoration on a materials advance? When the cell, tissue, or animal data do not carry the story, the manuscript reads as an Advanced Functional Materials paper, and the editor declines it or offers a transfer to a sister journal.

The fix is to move the biological validation from supporting to load-bearing in the abstract, the main figures, and the graphical abstract before upload.

Check whether your Advanced Healthcare Materials biological validation carries the healthcare claim →

In vitro-only claims that need in vivo evidence. The parallel failure is a cell-culture result framed as if it already proved a therapeutic, regenerative, or implant outcome. A viability or proliferation assay is used to assert that a scaffold regenerates tissue, that a nanoparticle treats a disease, or that a coating prevents infection in practice.

Reviewers in healthcare materials treat the gap between in vitro behavior and in vivo function as the whole point of the field, so an efficacy claim with no animal model, or no honest in-vitro-bounded framing, reads as overstated.

The methods and results sections are where this is decided: if the manuscript claims a healthcare effect that the experiments do not reach, the contribution is not yet ready for this journal regardless of how clean the in vitro data look.

Check if your Advanced Healthcare Materials claims match your in vivo evidence →

"Biocompatible" asserted from a single thin assay. Biocompatibility is a claim that requires an evidence package, and the recurring error is treating it as a checkbox. A single MTT or live-dead assay at one concentration and one timepoint is presented as proof of biocompatibility, with no controls, no dose-response, no degradation or host-response data, and no statistical analysis of the cell results. Reviewers read that as a token gesture rather than a result.

AHM expects a biocompatibility claim to be defended the way any other central claim is defended, with controls, replicates, and a sample size that supports the statistical analysis. A manuscript that asserts biocompatibility on one assay is one of the most predictable revision-or-reject triggers at this journal.

Check whether your Advanced Healthcare Materials biocompatibility data support the claim →

Scope drift to pure materials, plus ethics gaps. The last pattern combines two things editors catch fast. First, scope drift: the genuine contribution is a material property, a device-fabrication method, or a self-assembly mechanism, and the healthcare framing is added for fit. AHM editors are healthcare-materials specialists, and they identify quickly when the human-health advance is the setting rather than the subject.

Second, the mechanical gaps that bypass review entirely: animal experiments missing the Experimental-Section statement that names the approving authority and committees, with accreditation numbers where applicable, or in vivo work that does not follow ARRIVE reporting. Either gap can return the submission before an editor evaluates the science.

This guide tells you what Advanced Healthcare Materials editors look for; a Manusights review tells you whether YOUR paper passes that screen. A Manusights review checks the biological validation, the biocompatibility evidence, the in vitro-to-in vivo logic, the format choice, and the ethics statements against the editorial bar this journal applies before peer review. Paid Manusights reviews include a 60-day money-back guarantee, and we do not train models on submitted manuscripts.

Before submitting, an Advanced Healthcare Materials validation and scope readiness check tests whether your biological validation, biocompatibility evidence, and scope framing clear the editorial bar this journal applies before peer review.

This guide was built from Advanced Healthcare Materials author guidelines, the Wiley Guide for Authors, the journal's aims and scope, the Advanced portfolio transfer network, and Manusights pre-submission review patterns from healthcare-materials manuscripts. We checked the article-type and length guidance, the single-anonymous review model, the preprint policy, and the ARRIVE ethics requirement against Wiley's own pages (re-read on 2026-10-10), and we cross-checked review-timing ranges against SciRev community data and Clarivate JCR metrics. The failure patterns describe what we see most often when biomaterials manuscripts come through pre-submission review for this journal.

Use this page before you upload, when the official instructions cannot answer the real question: whether your biological validation, biocompatibility evidence, in vitro-to-in vivo logic, format choice, and scope framing are already defensible. Source limitation: Wiley updates format details, charges, and policies after this review date, so confirm administrative specifics against the journal's official pages before submission. For a read on the draft itself, run a manuscript readiness check.

• Acta Biomaterialia submission guide
• Biomaterials Science submission guide
• Journal of Controlled Release submission guide
• Advanced Materials submission guide
• For the broader cluster, see the biomaterials journals overview.

Before you upload, run your manuscript through an Advanced Healthcare Materials submission package check to catch the validation, biocompatibility, and scope issues editors filter for on first read. No cost, one file (/ai-review).

Fit failures are quiet. They show up as a desk rejection with no detail. Run a scope-fit check on Advanced Healthcare Materials before I reformat.